Key Points
- CareDx director Hannah Valantine sold 12,103 shares on June 15 at an average price of $23.11, totaling about $279,700. The sale reduced her holdings by 24.81% and was made under a pre-arranged Rule 10b5-1 trading plan.
- CareDx recently posted stronger-than-expected quarterly results, with EPS of $0.34 versus the $0.11 consensus estimate and revenue of $117.7 million, up 39.3% year over year. The company also exceeded revenue expectations for the quarter.
- Analyst sentiment is mixed, but the overall view is Hold: one analyst rates the stock Buy, four Hold, and one Sell, with a consensus price target of $25.00. Shares were trading near their 52-week high, with a recent open of $23.25 versus a 52-week range of $10.96 to $24.85.
CareDx, Inc. (NASDAQ:CDNA - Get Free Report) Director Hannah Valantine sold 12,103 shares of the business's stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $23.11, for a total transaction of $279,700.33. Following the completion of the sale, the director owned 36,686 shares of the company's stock, valued at approximately $847,813.46. The trade was a 24.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
CareDx Stock Performance
Shares of CDNA opened at $23.25 on Wednesday. The firm has a market cap of $1.20 billion, a price-to-earnings ratio of -145.31 and a beta of 2.49. CareDx, Inc. has a fifty-two week low of $10.96 and a fifty-two week high of $24.85. The firm has a 50 day moving average price of $21.03 and a 200-day moving average price of $19.70.
CareDx (NASDAQ:CDNA - Get Free Report) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.34 earnings per share for the quarter, topping analysts' consensus estimates of $0.11 by $0.23. The firm had revenue of $117.70 million during the quarter, compared to analyst estimates of $102.03 million. CareDx had a negative net margin of 2.01% and a negative return on equity of 2.65%. The business's quarterly revenue was up 39.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.09 EPS. As a group, equities research analysts predict that CareDx, Inc. will post 0.22 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several brokerages recently commented on CDNA. Weiss Ratings reaffirmed a "sell (d)" rating on shares of CareDx in a research note on Wednesday, May 27th. Wall Street Zen raised shares of CareDx from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 3rd. Wells Fargo & Company lifted their target price on shares of CareDx from $18.00 to $21.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 25th. Finally, BTIG Research lifted their target price on shares of CareDx from $26.00 to $28.00 and gave the stock a "buy" rating in a research note on Wednesday, April 29th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $25.00.
Get Our Latest Stock Analysis on CDNA
Institutional Inflows and Outflows
Several hedge funds have recently made changes to their positions in the company. Price T Rowe Associates Inc. MD increased its stake in shares of CareDx by 1.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 39,218 shares of the company's stock worth $739,000 after buying an additional 711 shares during the period. The Manufacturers Life Insurance Company increased its position in CareDx by 4.8% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,742 shares of the company's stock valued at $542,000 after purchasing an additional 1,280 shares during the period. Quarry LP purchased a new position in CareDx during the 4th quarter valued at $25,000. Allspring Global Investments Holdings LLC increased its position in CareDx by 9.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 19,091 shares of the company's stock valued at $365,000 after purchasing an additional 1,675 shares during the period. Finally, FNY Investment Advisers LLC purchased a new position in CareDx during the 3rd quarter valued at $31,000.
About CareDx
(
Get Free Report)
CareDx, Inc (NASDAQ: CDNA) is a precision diagnostics company focused on the care of transplant patients. The firm develops and commercializes non‐invasive tests designed to detect organ transplant rejection and infection risk, helping physicians make informed management decisions throughout the post‐transplant journey.
The company's core product portfolio includes AlloMap®, a gene expression profiling test for heart transplant recipients, and AlloSure®, a donor‐derived cell‐free DNA assay used primarily in kidney transplant monitoring.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
